Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry. (December 2021)

• Record Type: Journal Article
• Authors: Plesa, Adriana; Roumier, Christophe; Gutrin, Joris; Larcher, Marie-Virginie; Balsat, Marie; Cadassou, Octavia; Barraco, Fiorenza; Fossard, Gaëlle; Baudouin, Amandine; Labussière, Hélène; Tigaud, Isabelle; Ducastelle, Sophie; Hayette, Sandrine; Sujobert, Pierre; Heiblig, Maël; Elhamri, Mohamed; Thomas, Xavier
• Is Part Of: Leukemia research. Volume 111(2021)
• Publication Date: 2021-12
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2021.106673
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: Our short series confirms the high response rate with CPX-351 in t-AML or MRC-AML. The high rate of MRD negativity supports prior evidence that CPX-351 contributes to long-term remission. MFC monitoring was confirmed as a reliable approach to assess response to treatment.